Nanoparticles for Manipulation of the Developmental Wnt, Hedgehog, and Notch Signaling Pathways in Cancer

被引:0
作者
D. M. Valcourt
M. N. Dang
J. Wang
E. S. Day
机构
[1] University of Delaware,Department of Biomedical Engineering
[2] University of Delaware,Department of Materials Science & Engineering
[3] Helen F. Graham Cancer Center & Research Institute,undefined
来源
Annals of Biomedical Engineering | 2020年 / 48卷
关键词
Small molecule; RNA interference; Antibody; Multivalency; Drug delivery; Gene regulation; Nanocarrier; Nanomedicine;
D O I
暂无
中图分类号
学科分类号
摘要
The Wnt, Hedgehog, and Notch signaling pathways play a crucial role in early development and the maintenance of adult tissues. When dysregulated, these developmental signaling pathways can drive the formation and progression of cancer by facilitating cell survival, proliferation, and stem-like behavior. While this makes these pathways promising targets for therapeutic intervention, their pharmacological inhibition has been challenging due to the substantial complexity that exists within each pathway and the complicated crosstalk that occurs between the pathways. Recently, several small molecule inhibitors, ribonucleic acid (RNA) molecules, and antagonistic antibodies have been developed that can suppress these signaling pathways in vitro, but many of them face systemic delivery challenges. Nanoparticle-based delivery vehicles can overcome these challenges to enhance the performance and anti-cancer effects of these therapeutic molecules. This review summarizes the mechanisms by which the Wnt, Hedgehog, and Notch signaling pathways contribute to cancer growth, and discusses various nanoparticle formulations that have been developed to deliver small molecules, RNAs, and antibodies to cancer cells to inhibit these signaling pathways and halt tumor progression. This review also outlines some of the challenges that these nanocarriers must overcome to achieve therapeutic efficacy and clinical translation.
引用
收藏
页码:1864 / 1884
页数:20
相关论文
共 912 条
  • [1] Aburjania Z(2018)The role of Notch3 in cancer Oncologist 23 1-12
  • [2] Jang S(2016)Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer Oncotarget 7 86803-86815
  • [3] Whitt J(2009)Antibody-conjugated nanoparticles for biomedical applications J. Nanomater. 5 e9094-533
  • [4] Jaskula-Stzul R(2010)Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors PLoS ONE 125 523-12717
  • [5] Chen H(2006)Secretion of Wnt ligands requires Evi, a conserved transmembrane protein Cell 4 a008151-4742
  • [6] Rose JB(2012)Signaling in cell differentiation and morphogenesis Cold Spring Harb. Perspect. Biol. 9 12709-10
  • [7] Arend RC(2017)Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth Nanoscale 75 4728-429
  • [8] Londoño-Joshi AI(2015)Multivalent forms of the Notch ligand DLL-1 enhance antitumor T-cell immunity in lung cancer and improve efficacy of EGFR-targeted therapy Cancer Res. 3 1-15
  • [9] Gangrade A(2017)Poly-lactic-co-glycolic acid nanoformulation of small molecule antagonist GANT61 for cancer annihilation by modulating hedgehog pathway NanoWorld J. 303–313 2016-10985
  • [10] Katre AA(1863)The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways Biochim. Biophys. Acta 14 416-2748